Evaluation of the cardioprotective potential of extracellular vesicles – a systematic review and meta-analysis

Wendt, Sebastian; Goetzenich, Andreas; Goettsch, Claudia; Stoppe, Christian; Berne, Christian; Kraemer, Sandra; Benstoem, Carina

doi:10.1038/s41598-018-33862-5

Cited by 31 publications

(22 citation statements)

References 71 publications

(221 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes have been expected to be a new hot issue in the field of markers for cardiovascular diseases due to their specific diagnostic value and unknown underlying mechanisms [116,117,118]. Exosome RNA and proteins are demonstrated to be related to cardiac dysfunction and mediate cardioprotective abilities [119,120,121,122]. Previous studies have found that exosomes containing AT1Rs were isolated from mice undergoing cardiac pressure overload.…”

Section: Research and Application Prospects In Clinical And Forensmentioning

confidence: 99%

BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine

Cao

Jia

Zhu

2019

IJMS

205

146

View full text Add to dashboard Cite

Currently, brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are widely used as diagnostic biomarkers for heart failure (HF) and cardiac dysfunction in clinical medicine. They are also used as postmortem biomarkers reflecting cardiac function of the deceased before death in forensic medicine. Several previous studies have reviewed BNP and NT-proBNP in clinical medicine, however, few articles have reviewed their application in forensic medicine. The present article reviews the biological features, the research and application status, and the future research prospects of BNP and NT-proBNP in both clinical medicine and forensic medicine, thereby providing valuable assistance for clinicians and forensic pathologists.

show abstract

Section: Research and Application Prospects In Clinical And Forensmentioning

confidence: 99%

BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine

Cao

Jia

Zhu

2019

IJMS

205

146

View full text Add to dashboard Cite

show abstract

“…Total RNA sequencing of EVs from human serum revealed that tRNA and miRNA made up approximately 15% of EV RNA [35]. Among the identified EV RNAs, miRNA has been closely associated with CVD [44,45,46].…”

Section: Extracellular Vesicle Contents In Cvdmentioning

confidence: 99%

Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers

Chong

Lee

Huang

et al. 2019

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) represent the leading cause of morbidity and mortality globally. The emerging role of extracellular vesicles (EVs) in intercellular communication has stimulated renewed interest in exploring the potential application of EVs as tools for diagnosis, prognosis, and therapy in CVD. The ubiquitous nature of EVs in biological fluids presents a technological advantage compared to current diagnostic tools by virtue of their notable stability. EV contents, such as proteins and microRNAs, represent specific signatures of cellular activation or injury. This feature positions EVs as an alternative source of biomarkers. Furthermore, their intrinsic activity and immunomodulatory properties offer EVs unique opportunities to act as therapeutic agents per se or to serve as drug delivery carriers by acting as miniaturized vehicles incorporating bioactive molecules. In this article, we aim to review the recent advances and applications of EV-based biomarkers and therapeutics. In addition, the potential of EVs as a drug delivery and theranostic platform for CVD will also be discussed.

show abstract

“…The most accepted mechanism of formation and release is the shedding after membrane budding [147]. Therefore, their cell of origin is defined by specific surface markers [149].…”

Section: Ev and Cardioprotectionmentioning

confidence: 99%

Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration

Caccioppo

Franchin

Grosso

et al. 2019

IJMS

View full text Add to dashboard Cite

Ischemic diseases in an aging population pose a heavy social encumbrance. Moreover, current therapeutic approaches, which aimed to prevent or minimize ischemia-induced damage, are associated with relevant costs for healthcare systems. Early reperfusion by primary percutaneous coronary intervention (PPCI) has undoubtedly improved patient’s outcomes; however, the prevention of long-term complications is still an unmet need. To face these hurdles and improve patient’s outcomes, novel pharmacological and interventional approaches, alone or in combination, reducing myocardium oxygen consumption or supplying blood flow via collateral vessels have been proposed. A number of clinical trials are ongoing to validate their efficacy on patient’s outcomes. Alternative options, including stem cell-based therapies, have been evaluated to improve cardiac regeneration and prevent scar formation. However, due to the lack of long-term engraftment, more recently, great attention has been devoted to their paracrine mediators, including exosomes (Exo) and microvesicles (MV). Indeed, Exo and MV are both currently considered to be one of the most promising therapeutic strategies in regenerative medicine. As a matter of fact, MV and Exo that are released from stem cells of different origin have been evaluated for their healing properties in ischemia reperfusion (I/R) settings. Therefore, this review will first summarize mechanisms of cardiac damage and protection after I/R damage to track the paths through which more appropriate interventional and/or molecular-based targeted therapies should be addressed. Moreover, it will provide insights on novel non-invasive/invasive interventional strategies and on Exo-based therapies as a challenge for improving patient’s long-term complications. Finally, approaches for improving Exo healing properties, and topics still unsolved to move towards Exo clinical application will be discussed.

show abstract

Evaluation of the cardioprotective potential of extracellular vesicles – a systematic review and meta-analysis

Cited by 31 publications

References 71 publications

BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine

BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine

Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers

Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration

Contact Info

Product

Resources

About